Article
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
AIDS (London, England) - 28 Feb 2006
Mayer Kenneth H, Maslankowski Lisa A, Gai Fang, El-Sadr Wafaa M, Justman Jessica, Kwiecien Antonia, Mâsse Benoît, Eshleman Susan H, Hendrix Craig, Morrow Kathleen, Rooney James F, Soto-Torres Lydia
Abstract excerpt
OBJECTIVES: To establish the highest practical dose and frequency (HPDF) of 0.3% or 1% tenofovir vaginal gel applied once or twice daily by sexually abstinent HIV-uninfected women, and to evaluate the safety, tolerability and systemic pharmacokinetics of the HPDF in abstinent and sexually active HIV-negative and HIV-infected women. METHODS: Eighty-four women, enrolled in sequential cohorts, used the study product...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.